Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 8/2005

01-08-2005 | Contrast Media

Safety of MR liver specific contrast media

Authors: Marie-France Bellin, Judith A. W. Webb, Aart J. Van Der Molen, Henrik S. Thomsen, Sameh K. Morcos, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)

Published in: European Radiology | Issue 8/2005

Login to get access

Abstract

Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.
Literature
1.
Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426–435CrossRef
2.
Bluemke DA, Weber TM, Rubin D et al (2003) Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 228:457–464PubMed
3.
Marti-Bonmati L, Fog AF, Op de Beeck B, Kane P, Fagertun H (2003) Safety and efficacy of mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 13:1685–1692
4.
Ros PR, Freeny PC, Harms SE et al (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed
5.
Kopp AF, Laniado M, Dammann F et al (1997) MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 204:749–756
6.
Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291
7.
Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688–2698
8.
Bellin MF, Zaim S, Auberton E et al (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193:657–663PubMed
9.
Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ (2001) Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SHU 555 A) J Magn Reson Imaging 14:595–601CrossRef
10.
Reimer P, Balzer T (2003) Ferucarbotran (Resovist), a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed
11.
Wang YXJ, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331CrossRefPubMed
12.
Stark DD, Weissleder R, Elizondo G et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168:297–301PubMed
13.
Precetti-Morel S, Bellin MF, Ghebontni L et al (1999) Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. Eur Radiol 9:1535–1542CrossRef
14.
Montet X, Lazeyras F, Howarth N et al (2004) Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 29:60–70PubMed
15.
Federle M, Chezmar J, Rubin DL et al (2000) Efficacy and safety of mangafodipir trisodium (MnDPDP) Injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 12:689–701
16.
Elizondo G, Fretz CJ, Stark DD et al (1991) Preclinical evaluation of Mn-DPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73–78
17.
Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quah SC (1991) Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 178:79–82
18.
Thomsen HS, Svendsen O, Klastrup S (2004) Increased manganese concentration in the liver after oral intake. Acad Radiol 11:38–44CrossRefPubMed
19.
Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J (2004) Oral manganese for liver imaging at three different field strengths. Acad Radiol 11:630–636
20.
Gallez B, Bacic G, Swartz HM (1996) Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med 35:14–19
21.
Hustvedt SO, Grant D, Southon TE, Zeck K (1997) Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol 38:690–699
22.
Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes HS (1997) MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 38:631–637
23.
Marti-Bonmati L, Torregrosa A, Miguel A, Molla E, Dosda R, Arana E (2001) Safety and efficacy of a bolus administration of mangafodipir trisodium in MR studies (poster). Ninth scientific meeting ISMRM and 14th annual meeting ESMRMB, Glasgow. Proc ISMRM, p 2036
24.
Rummeny E, Ehrenheim C, Gehl HB et al (1991) Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of livers tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 26(Suppl 1):S142–S145; Discussion S150–S155
25.
Aicher KP, Laniado M, Kopp AF, Gronewaller E, Duda SH, Claussen CD (1993) Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging 3:731–737
26.
Wang C, Ahlstrom H, Ekholm S et al (1997) Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicenter study. Acta Radiol 38:643–649PubMed
27.
Blume J, Palmie S, Aue B et al (1994) Pancreatic contrast enhancement with Mn-bis pyridoxal ethylene diamine diacetic acid and the influence of a hormonal stimulation of the pancreas in pigs. Acad Radiol 1:253–260
28.
Mayo-Smith WW, Schima W, Saini S, Slater GJ, McFarland EG (1998) Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium. Am J Roentgenol 170:649–652
29.
Kirchin MA, Pirovano G, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809
30.
Kirchin MA, Pirovano G, Venetianer C, Spinazzi A (2001) Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281–294CrossRefPubMed
31.
Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796CrossRef
32.
Hamm B, Kirchin M, Pirovano G, Spinazzi A (1999) Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr 23(Suppl 1):S53–S60
33.
Caudana R, Morana G, Pirovano GP et al (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520
34.
Peterstein J, Spinazzi A, Giovagnoni A et al (2000) Evaluation of the efficacy of gadobenate dimeglumine in magnetic resonance imaging of focal liver lesions: a multicenter phase III clinical study. Radiology 215:727–736
35.
Vogl TJ, Stupavsky A, Pegios W et al (1997) Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 205:721–728
36.
Manfredi R, Maresca G, Baron RL et al (1998) Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 8:862–867
37.
Manfredi R, Maresca G, Baron RL et al (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710CrossRefPubMed
38.
Grazioli L, Morana G, Caudana R et al (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathological findings. Invest Radiol 35:25–34
39.
Rosati G, Pirovano G, Spinazzi A (1994) Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 29:S183–S185
40.
Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59–64
41.
Giovagnoni A, Paci E (1996) Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/dimeg). Magn Reson Imaging Clin N Am 4:61–72
42.
Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578CrossRefPubMed
43.
Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7:126–132CrossRefPubMed
44.
Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792
45.
Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183PubMed
46.
Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255–262
47.
Huppertz A, Balzer T, Blakeborough A et al for the European EOB Study Group (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275PubMed
48.
Breuer J, Balzer T, Shamsi K, Carter R (2003) Clinical experience from phase II and phase III studies for Gd-EOB-DTPA: a new liver specific MR contrast agent. Eur Radiol 13(Suppl 2):S109
49.
Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ (2002) Gadolinium-ethoxybenzyl–diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680–684CrossRef
Metadata
Title
Safety of MR liver specific contrast media
Authors
Marie-France Bellin
Judith A. W. Webb
Aart J. Van Der Molen
Henrik S. Thomsen
Sameh K. Morcos
Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
European Radiology / Issue 8/2005
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-004-2612-x

Other articles of this Issue 8/2005

European Radiology 8/2005 Go to the issue

Urogenital

Manifestation of Hodgkin’s lymphoma in an adrenal myelolipoma

Urogenital

Efficacy of transvaginal contrast-enhanced MRI in the early staging of cervical carcinoma

Musculoskeletal

CT volumetry of intravertebral cement after kyphoplasty. Comparison of polymethylmethacrylate and calcium phosphate in a 12-month follow-up

Chest

Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT

Interpretation Corner

Unusual Cause of Dysphagia (2005: 8a)

Urogenital

Evaluation of imaging-guided fine-needle percutaneous biopsy of renal masses